CL2012003202A1 - Metodo para tratar una infeccion gastrointestinal recurrente de clostridium difficile, que comprende la administracion de fidaxomicina y donde el sujeto ha sido sometido a un tratamiento previo para combatir dicha infeccion. - Google Patents

Metodo para tratar una infeccion gastrointestinal recurrente de clostridium difficile, que comprende la administracion de fidaxomicina y donde el sujeto ha sido sometido a un tratamiento previo para combatir dicha infeccion.

Info

Publication number
CL2012003202A1
CL2012003202A1 CL2012003202A CL2012003202A CL2012003202A1 CL 2012003202 A1 CL2012003202 A1 CL 2012003202A1 CL 2012003202 A CL2012003202 A CL 2012003202A CL 2012003202 A CL2012003202 A CL 2012003202A CL 2012003202 A1 CL2012003202 A1 CL 2012003202A1
Authority
CL
Chile
Prior art keywords
infection
fidaxomycin
combat
administration
treating
Prior art date
Application number
CL2012003202A
Other languages
English (en)
Inventor
Youe-Kong Shue
Sherwood Gorbach
Pamela Sears
Original Assignee
Optimer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44992320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003202(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Optimer Pharmaceuticals Inc filed Critical Optimer Pharmaceuticals Inc
Publication of CL2012003202A1 publication Critical patent/CL2012003202A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Método para tratar una infección gastrointestinal recurrente de clostridium difficile, que comprende la administración de fidaxomicina y donde el sujeto ha sido sometido a un tratamiento previo para combatir dicha infección.
CL2012003202A 2010-05-18 2012-11-16 Metodo para tratar una infeccion gastrointestinal recurrente de clostridium difficile, que comprende la administracion de fidaxomicina y donde el sujeto ha sido sometido a un tratamiento previo para combatir dicha infeccion. CL2012003202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34592310P 2010-05-18 2010-05-18

Publications (1)

Publication Number Publication Date
CL2012003202A1 true CL2012003202A1 (es) 2013-07-12

Family

ID=44992320

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003202A CL2012003202A1 (es) 2010-05-18 2012-11-16 Metodo para tratar una infeccion gastrointestinal recurrente de clostridium difficile, que comprende la administracion de fidaxomicina y donde el sujeto ha sido sometido a un tratamiento previo para combatir dicha infeccion.

Country Status (9)

Country Link
US (1) US20140315838A1 (es)
AU (1) AU2011255633B2 (es)
BR (1) BR112012029262A8 (es)
CA (1) CA2799531A1 (es)
CL (1) CL2012003202A1 (es)
CO (1) CO6670519A2 (es)
MX (1) MX2012013372A (es)
PE (1) PE20130308A1 (es)
WO (1) WO2011146624A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6134739B2 (ja) 2012-01-23 2017-05-24 サンタリス ファーマシューティカルズ インコーポレイテッド ビャクダン油およびクロストリジウム感染症に関連するその使用
US20150157653A1 (en) * 2012-03-16 2015-06-11 Optimer Pharmaceuticals, Inc. Prevention of Clostridium Difficile Infection in High Risk Patients
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
CN110037992B (zh) * 2019-05-28 2021-05-28 杭州华东医药集团新药研究院有限公司 一种稳定的非达霉素组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins

Also Published As

Publication number Publication date
BR112012029262A8 (pt) 2018-06-12
CA2799531A1 (en) 2011-11-24
US20140315838A1 (en) 2014-10-23
WO2011146624A2 (en) 2011-11-24
CO6670519A2 (es) 2013-05-15
MX2012013372A (es) 2013-05-01
BR112012029262A2 (pt) 2017-07-11
PE20130308A1 (es) 2013-04-06
AU2011255633B2 (en) 2014-09-11
AU2011255633A1 (en) 2013-01-10
WO2011146624A9 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
CL2012003385A1 (es) Tratamiento para la incontinencia.
BR112013032229A2 (pt) método de tratamento hidrocatalítico hidrotérmico de biomassa, e, composição
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
UY34327A (es) ?composiciones y métodos para controlar malezas comprendiendo un polinucleótido y agente de transferencia, y que modulan 4-hidrofenil-piruvato-dioxigenasa?.
WO2014052836A3 (en) Methods and compositions for treating infection
WO2014113729A3 (en) Methods of treating cholangiocarcinoma
BR112012001372A2 (pt) comprimido, e, métodos para preparar um comprimido e para a profilaxia ou tratamento de hiperfosfatemia.
CR20120202A (es) Métodos y composiciones para tratar cáncer
UY34328A (es) ?composiciones y métodos para controlar malezas comprendiendo un polinucleótido y agente de transferencia, y que modulan protoporfirinógeno ix oxidasa?.
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
MY163031A (en) Method of treating obesity using antioxidant inflammation modulators
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
EA201690582A1 (ru) Модуляторы фактора в комплемента
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
PH12016502062A1 (en) Compositions and methods for modulating completent factor b expression
WO2012116010A3 (en) Antibiotic tolerance inhibitors
MY172699A (en) Implantable medical devices with increased immune tolerance, and methods for making and implanting
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
BR112015004515A2 (pt) composição imunogênica
WO2012106427A3 (en) Methods for treating diabetic foot ulcers
IN2014KN02620A (es)
WO2014124307A3 (en) Targeted theranostics
CL2012003202A1 (es) Metodo para tratar una infeccion gastrointestinal recurrente de clostridium difficile, que comprende la administracion de fidaxomicina y donde el sujeto ha sido sometido a un tratamiento previo para combatir dicha infeccion.
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
WO2013162981A3 (en) Breast implant spacers for the treatment of periprosthetic breast implant infections